Jaguar Health Inc
JAGX1.130USD
+0.040+3.67%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
4.17MMarket Cap
LossP/E TTM
More Details of Jaguar Health Inc Company
Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
Jaguar Health Inc Info
Ticker SymbolJAGX
Company nameJaguar Health Inc
IPO dateMay 13, 2015
CEOConte (Lisa A)
Number of employees49
Security typeOrdinary Share
Fiscal year-endMay 13
Address200 Pine Street Suite 400
CitySAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94104
Phone14153718300
Websitehttps://jaguar.health/
Ticker SymbolJAGX
IPO dateMay 13, 2015
CEOConte (Lisa A)
Company Executives of Jaguar Health Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Pravin R. Chaturvedi, Ph.D.
Dr. Pravin R. Chaturvedi, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
202.00
+47.45%
Mr. Jonathan S. Wolin
Mr. Jonathan S. Wolin
Chief of Staff, General Counsel, Chief Compliance Officer
Chief of Staff, General Counsel, Chief Compliance Officer
197.00
+49.24%
Mr. Jonathan B. Siegel
Mr. Jonathan B. Siegel
Independent Director
Independent Director
45.00
--
Mr. John J. Micek, III
Mr. John J. Micek, III
Independent Director
Independent Director
--
--
Ms. Carol R. Lizak
Ms. Carol R. Lizak
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Steven R. King, Ph.D.
Dr. Steven R. King, Ph.D.
Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property, Secretary
Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property, Secretary
--
--
Dr. Anula K. Jayasuriya, M.D., Ph.D.
Dr. Anula K. Jayasuriya, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Ian Wendt
Mr. Ian Wendt
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Lisa A. Conte
Ms. Lisa A. Conte
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. James J. Bochnowski
Mr. James J. Bochnowski
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Pravin R. Chaturvedi, Ph.D.
Dr. Pravin R. Chaturvedi, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
202.00
+47.45%
Mr. Jonathan S. Wolin
Mr. Jonathan S. Wolin
Chief of Staff, General Counsel, Chief Compliance Officer
Chief of Staff, General Counsel, Chief Compliance Officer
197.00
+49.24%
Mr. Jonathan B. Siegel
Mr. Jonathan B. Siegel
Independent Director
Independent Director
45.00
--
Mr. John J. Micek, III
Mr. John J. Micek, III
Independent Director
Independent Director
--
--
Ms. Carol R. Lizak
Ms. Carol R. Lizak
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Steven R. King, Ph.D.
Dr. Steven R. King, Ph.D.
Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property, Secretary
Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property, Secretary
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 18
Updated: Thu, Dec 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
13.22%
Iliad Research & Trading, L.P.
9.70%
Brown Stone Capital Ltd
3.56%
DRW Securities, LLC
2.00%
WBW Trust One
1.73%
Other
69.78%
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
13.22%
Iliad Research & Trading, L.P.
9.70%
Brown Stone Capital Ltd
3.56%
DRW Securities, LLC
2.00%
WBW Trust One
1.73%
Other
69.78%
Shareholder Types
Shareholders
Proportion
Corporation
29.79%
Investment Advisor
2.06%
Individual Investor
1.17%
Investment Advisor/Hedge Fund
0.10%
Hedge Fund
0.09%
Other
66.79%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
32
13.70K
0.68%
-88.10K
2025Q2
46
243.00K
13.10%
+147.33K
2025Q1
51
102.25K
9.10%
+15.99K
2024Q4
58
1.15M
16.97%
+379.12K
2024Q3
61
1.40M
25.15%
+578.82K
2024Q2
62
807.73K
26.56%
+336.48K
2024Q1
65
210.88K
23.56%
+139.83K
2023Q4
66
157.05K
30.73%
+119.23K
2023Q3
72
88.91K
41.12%
+74.12K
2023Q2
76
63.74K
33.22%
+52.52K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lincoln Alternative Strategies LLC
600.00K
17.02%
+600.00K
--
Aug 28, 2025
Iliad Research & Trading, L.P.
31.83K
0.9%
+16.08K
+102.12%
Jul 18, 2024
Intracoastal Capital, L.L.C.
27.00K
0.77%
+27.00K
--
May 27, 2025
Chaturvedi (Pravin R)
137.00
0%
+68.00
+98.55%
Jul 08, 2025
Lizak (Carol R.)
94.00
0%
+46.00
+95.83%
Jul 08, 2025
Siegel (Jonathan B)
45.00
0%
--
--
Jul 08, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 18, 2025
Merger
25→1
Mar 18, 2025
Merger
25→1
Mar 18, 2025
Merger
25→1
Mar 18, 2025
Merger
25→1
May 20, 2024
Merger
60→1
May 20, 2024
Merger
60→1
Date
Type
Ratio
Mar 18, 2025
Merger
25→1
Mar 18, 2025
Merger
25→1
Mar 18, 2025
Merger
25→1
Mar 18, 2025
Merger
25→1
May 20, 2024
Merger
60→1
May 20, 2024
Merger
60→1
May 20, 2024
Merger
60→1
May 20, 2024
Merger
60→1
Jan 20, 2023
Merger
75→1
Jan 20, 2023
Merger
75→1
View more
FAQs
Who are the top five shareholders of Jaguar Health Inc?
The top five shareholders of Jaguar Health Inc are:
Lincoln Alternative Strategies LLC holds 600.00K shares, accounting for 17.02% of the total shares.
Iliad Research & Trading, L.P. holds 31.83K shares, accounting for 0.90% of the total shares.
Intracoastal Capital, L.L.C. holds 27.00K shares, accounting for 0.77% of the total shares.
Chaturvedi (Pravin R) holds 137.00 shares, accounting for 0.00% of the total shares.
Lizak (Carol R.) holds 94.00 shares, accounting for 0.00% of the total shares.
Lincoln Alternative Strategies LLC holds 600.00K shares, accounting for 17.02% of the total shares.
Iliad Research & Trading, L.P. holds 31.83K shares, accounting for 0.90% of the total shares.
Intracoastal Capital, L.L.C. holds 27.00K shares, accounting for 0.77% of the total shares.
Chaturvedi (Pravin R) holds 137.00 shares, accounting for 0.00% of the total shares.
Lizak (Carol R.) holds 94.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Jaguar Health Inc?
The top three shareholder types of Jaguar Health Inc are:
Lincoln Alternative Strategies LLC
Iliad Research & Trading, L.P.
Brown Stone Capital Ltd
Lincoln Alternative Strategies LLC
Iliad Research & Trading, L.P.
Brown Stone Capital Ltd
How many institutions hold shares of Jaguar Health Inc (JAGX)?
As of 2025Q3, 32 institutions hold shares of Jaguar Health Inc, with a combined market value of approximately 13.70K, accounting for 0.68% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -12.42%.
What is the biggest source of revenue for Jaguar Health Inc?
In --, the -- business generated the highest revenue for Jaguar Health Inc, amounting to -- and accounting for --% of total revenue.
